Certolizumab pegol 200mg/1ml solution for injection pre-filled disposable devices
NHS hospitals in England used £47,714,095 of indicative cost of Certolizumab pegol 200mg/1ml solution for injection pre-filled disposable devices in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 8.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Certolizumab pegol 200mg/1ml solution for injection pre-filled disposable devices: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Certolizumab pegol 200mg/1ml solution for injection pre-filled disposable devices most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Leeds Teaching Hpls Nhs Trust | £2,079,935 |
| Barts Health Nhs Trust | £1,490,060 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,462,533 |
| The Royal Wolverhampton Nhs Trust | £1,305,590 |
| Royal Free London Nhs Foundation Trust | £1,261,618 |
| Manchester University Nhs Ft | £1,220,863 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,098,240 |
| Southend Univ Hosp Nhs Foundation Trust | £1,078,935 |
| Salford Royal Nhs Foundation Trust | £1,066,780 |
| Aintree University Hospital Nhs Ft | £965,250 |
The primary-care picture
Certolizumab pegol is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Certolizumab pegol medicine page.